JP2013509435A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509435A5
JP2013509435A5 JP2012537131A JP2012537131A JP2013509435A5 JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5 JP 2012537131 A JP2012537131 A JP 2012537131A JP 2012537131 A JP2012537131 A JP 2012537131A JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5
Authority
JP
Japan
Prior art keywords
patient
injectable
depot
dose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054807 external-priority patent/WO2011053829A1/en
Publication of JP2013509435A publication Critical patent/JP2013509435A/ja
Publication of JP2013509435A5 publication Critical patent/JP2013509435A5/ja
Pending legal-status Critical Current

Links

JP2012537131A 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン Pending JP2013509435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
US61/256,696 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015237117A Division JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Publications (2)

Publication Number Publication Date
JP2013509435A JP2013509435A (ja) 2013-03-14
JP2013509435A5 true JP2013509435A5 (https=) 2013-12-19

Family

ID=43302985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537131A Pending JP2013509435A (ja) 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Country Status (12)

Country Link
US (2) US20110105536A1 (https=)
EP (1) EP2493473A1 (https=)
JP (2) JP2013509435A (https=)
KR (1) KR20120116401A (https=)
CN (1) CN102802631A (https=)
AU (2) AU2010313290A1 (https=)
BR (1) BR112012010195A2 (https=)
CA (1) CA2742393A1 (https=)
CL (1) CL2012001110A1 (https=)
MX (1) MX2012005083A (https=)
NZ (1) NZ599558A (https=)
WO (1) WO2011053829A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR102318070B1 (ko) 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
ES2950418T3 (es) * 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
RS65024B1 (sr) * 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2020356529A1 (en) 2019-09-25 2022-05-19 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
TW202210119A (zh) * 2020-09-02 2022-03-16 比利時商健生藥品公司 具有最佳化止擋件布置之預充填注射器
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
ES2981035T3 (es) * 2020-11-30 2024-10-07 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
JP2024511353A (ja) * 2021-03-17 2024-03-13 メドインセルル エス.エー. リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP1940834A2 (en) * 2006-08-14 2008-07-09 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone)
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법

Similar Documents

Publication Publication Date Title
JP2013509435A5 (https=)
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
JP2015187125A5 (https=)
JP2014114288A5 (https=)
JP2017031213A5 (https=)
JP2015512392A5 (https=)
RU2008138381A (ru) Режимы дозирования адреналина
JP2018510894A5 (https=)
JP2011511072A5 (https=)
JP2019196370A5 (https=)
JP2016514132A5 (https=)
SI2523688T1 (en) Formulation of antibodies and therapeutic regimes
JP2017538705A5 (https=)
JP2013543501A5 (https=)
FI3998078T3 (fi) Annoksensuurentamisentsyymikorvaushoito happaman sfingomyelinaasin puutoksen hoitamista varten
JP2010531879A5 (https=)
JP2018531605A5 (https=)
JP2019511506A5 (https=)
JP2023520004A5 (https=)
RU2019107146A (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
Gopalakrishna et al. Long-acting injectable aripiprazole: how might it fit in our tool box?
Remington et al. 2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation
JP2016515137A5 (https=)
RU2013150024A (ru) Способы контроля и лечения хронической боли с применением hcg